DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea
· Delayed Price · Currency is KRW 5,260.00
+270.00 (5.41%)
Last updated: Mar 25, 2025
DongKoo Bio & Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Net Income | 2,036 | 11,812 | 6,614 | 9,327 | 9,140 | Upgrade
|
| Depreciation & Amortization | 7,274 | 6,028 | 5,632 | 5,054 | 4,506 | Upgrade
|
| Loss (Gain) From Sale of Assets | -5.98 | 0 | -123.89 | 1.33 | 81.62 | Upgrade
|
| Asset Writedown & Restructuring Costs | 665.56 | - | - | 0 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -7,119 | -2,077 | 8,869 | -1,090 | -1,985 | Upgrade
|
| Loss (Gain) on Equity Investments | 13,112 | 660.61 | -118.28 | 1,733 | -726.96 | Upgrade
|
| Stock-Based Compensation | 251.89 | 224.51 | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | -193.35 | -52.82 | 40.44 | 241.76 | 1,370 | Upgrade
|
| Other Operating Activities | 2,295 | 1,697 | 331.91 | 638.04 | 1,744 | Upgrade
|
| Change in Accounts Receivable | 478.4 | -1,333 | -2,861 | 1,431 | 1,532 | Upgrade
|
| Change in Inventory | -6,632 | -12,838 | -6,686 | -1,897 | -7,192 | Upgrade
|
| Change in Accounts Payable | 4,389 | -3,093 | 2,715 | 2,399 | -2,040 | Upgrade
|
| Change in Other Net Operating Assets | 793.42 | 2,558 | 2,404 | 65.1 | 1,058 | Upgrade
|
| Operating Cash Flow | 17,344 | 3,585 | 16,819 | 17,903 | 7,489 | Upgrade
|
| Operating Cash Flow Growth | 383.75% | -78.68% | -6.05% | 139.06% | -21.23% | Upgrade
|
| Capital Expenditures | -21,866 | -13,845 | -4,978 | -4,266 | -5,268 | Upgrade
|
| Sale of Property, Plant & Equipment | 6 | 0.66 | 300.44 | 11.97 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -3,598 | -2,034 | -6,098 | -1,137 | -192.72 | Upgrade
|
| Investment in Securities | -18,433 | 11,851 | -16,287 | 6,202 | -6,072 | Upgrade
|
| Other Investing Activities | 583.28 | -106 | 39 | -366.43 | -1,059 | Upgrade
|
| Investing Cash Flow | -45,033 | -5,133 | -27,014 | 463.93 | -12,564 | Upgrade
|
| Short-Term Debt Issued | 47,029 | 7,500 | 15,000 | 70.75 | 10,000 | Upgrade
|
| Long-Term Debt Issued | 9,895 | 1,447 | - | - | - | Upgrade
|
| Total Debt Issued | 56,924 | 8,947 | 15,000 | 70.75 | 10,000 | Upgrade
|
| Short-Term Debt Repaid | -13,528 | - | - | - | -6,883 | Upgrade
|
| Long-Term Debt Repaid | -935.5 | -1,126 | -5,966 | -742.12 | -2,536 | Upgrade
|
| Total Debt Repaid | -14,463 | -1,126 | -5,966 | -742.12 | -9,419 | Upgrade
|
| Net Debt Issued (Repaid) | 42,461 | 7,821 | 9,034 | -671.37 | 581.47 | Upgrade
|
| Repurchase of Common Stock | -3,408 | -79.9 | -2,995 | -1,998 | - | Upgrade
|
| Dividends Paid | -3,313 | -3,038 | -2,804 | -942.94 | -942.92 | Upgrade
|
| Other Financing Activities | 1,454 | 49 | -50 | -76.1 | 0 | Upgrade
|
| Financing Cash Flow | 37,194 | 4,752 | 3,185 | -3,688 | -361.45 | Upgrade
|
| Foreign Exchange Rate Adjustments | 154.83 | -4.74 | -33.91 | -2.27 | -23.18 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | 0 | -0 | -0 | Upgrade
|
| Net Cash Flow | 9,660 | 3,199 | -7,043 | 14,676 | -5,460 | Upgrade
|
| Free Cash Flow | -4,522 | -10,260 | 11,841 | 13,637 | 2,221 | Upgrade
|
| Free Cash Flow Growth | - | - | -13.16% | 514.06% | -74.46% | Upgrade
|
| Free Cash Flow Margin | -1.81% | -4.76% | 6.07% | 8.79% | 1.59% | Upgrade
|
| Free Cash Flow Per Share | -166.62 | -371.76 | 426.63 | 482.57 | 78.50 | Upgrade
|
| Cash Interest Paid | 2,828 | 1,672 | 902.19 | 362.76 | 401.35 | Upgrade
|
| Cash Income Tax Paid | 2,775 | 4,104 | 3,076 | 1,392 | 730.99 | Upgrade
|
| Levered Free Cash Flow | -9,684 | -15,354 | -140.43 | 10,027 | - | Upgrade
|
| Unlevered Free Cash Flow | -7,875 | -14,254 | 509.14 | 10,286 | - | Upgrade
|
| Change in Net Working Capital | -2,193 | 13,685 | 4,571 | -5,549 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.